Divi’s Laboratories Limited reported a 63.6% rise in consolidated profit after tax to ₹1,127 crore for the quarter ended 30 September 2026, up from ₹689 crore a year earlier. The Hyderabad-based maker of active pharmaceutical ingredients, intermediates and nutraceutical ingredients told the stock exchanges on 7 November 2026 that revenue from operations grew 35.4% to ₹3,676 crore.

What Divi’s Q2 FY27 results show

The company’s board approved the unaudited standalone and consolidated results at a meeting in Hyderabad on 7 November 2026, which ran from 10.30 am to 11.40 am. Price Waterhouse Chartered Accountants LLP issued unmodified limited-review reports on both statements. In its exchange filing and press release, Divi’s reported these consolidated figures for the July–September quarter:

• Revenue from operations: ₹3,676 crore, up 35.4% from ₹2,715 crore
• Total income: ₹3,770 crore, against ₹2,860 crore a year earlier
• Profit before tax: ₹1,505 crore, up from ₹912 crore
• Profit after tax: ₹1,127 crore, up 63.6% from ₹689 crore
• Basic earnings per share (not annualised): ₹42.49, against ₹25.97
• Foreign-exchange gain: ₹24 crore, compared with a gain of ₹63 crore a year earlier

Against the June 2026 quarter, revenue from operations rose from ₹3,080 crore and profit after tax from ₹902 crore. Other API producers have also reported this season, including Aarti Drugs’ Q2 FY27 jump in profit on API and formulation growth.

How did standalone and first-half numbers compare?

On a standalone basis, Divi’s posted total income of ₹3,735 crore for the quarter, against ₹2,806 crore a year earlier, and profit after tax of ₹1,140 crore, up from ₹696 crore. Standalone revenue from operations was ₹3,647 crore and profit before tax was ₹1,520 crore.

For the half year ended 30 September 2026, consolidated total income rose to ₹6,907 crore from ₹5,389 crore and profit after tax to ₹2,029 crore from ₹1,234 crore. First-half revenue from operations was ₹6,756 crore, against ₹5,125 crore, while the forex gain narrowed to ₹17 crore from ₹102 crore. Standalone first-half profit after tax was ₹2,031 crore, up from ₹1,253 crore.

The standalone balance sheet showed inventories of ₹5,325 crore at 30 September 2026, against ₹3,711 crore at 31 March 2026, while property, plant and equipment rose to ₹7,451 crore from ₹6,514 crore. Cash paid for property, plant and equipment in the first half was ₹871 crore.

What does Divi’s manufacture?

A note to the results says the company makes active pharmaceutical ingredients, intermediates and nutraceutical ingredients, treated as a single reportable business segment. The consolidated statement includes two subsidiaries, Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG. Dr Kiran S Divi, whole-time director and chief executive officer, signed the results in Hyderabad.

The print comes as Indian drugmakers expand API capacity and clear overseas inspections, including Alkem’s Mandva API plant clearing a USFDA audit with zero Form 483 observations. It also follows other large Q2 updates such as Aurobindo Pharma’s Q2 FY27 record revenue and 32.5% profit rise.

Why Divi’s Q2 results matter for India’s API industry

Divi’s is one of India’s largest listed API and intermediates manufacturers, so a sharp rise in quarterly sales and profit is a closely watched signal for the export-oriented ingredients business. India as a whole saw pharma exports rise 4.9% to $16.14 billion in the first half of FY27, with Europe and ASEAN offsetting softer US shipments.

Key takeaways

• Divi’s Laboratories’ Q2 FY27 consolidated profit after tax rose 63.6% to ₹1,127 crore, with revenue from operations up 35.4% to ₹3,676 crore.
• First-half consolidated profit after tax increased to ₹2,029 crore from ₹1,234 crore a year earlier.
• The company makes APIs, intermediates and nutraceutical ingredients and reports them as a single business segment.

FAQ

When did Divi’s Laboratories report Q2 FY27 results?

The board approved the unaudited results for the quarter and half year ended 30 September 2026 at its meeting in Hyderabad on 7 November 2026.

What were Divi’s standalone Q2 FY27 numbers?

Standalone total income was ₹3,735 crore and profit after tax was ₹1,140 crore, compared with ₹2,806 crore and ₹696 crore a year earlier.

Featured image: Aerial view of Divi’s Laboratories’ manufacturing facility in Visakhapatnam. Photo: Divi’s Laboratories

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!